# Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer

> **NCT07730138** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 384 (estimated)

## Conditions studied

- Gastric Ulcer

## Interventions

- **DRUG:** DWP14012 40mg (Fexuprazan)
- **DRUG:** Lansoprazole 30mg

## Key facts

- **NCT ID:** NCT07730138
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-15
- **Primary completion:** 2028-04-15
- **Final completion:** 2028-10-15
- **Target enrollment:** 384 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730138, "Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*